Sutro Biopharma Inc. (STRO) Prices 6M Share Common Offering at $21/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St futures muted as bond yields resume climb; Walmart drops after results
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Pre-Open Stock Movers 12/08: (LXRX) (SFIX) (SMAR) Higher; (PEN) (CONN) (MRNS) Lower (more...)
December 8, 2020 9:22 AM ESTPre-Open Stock Movers
Lexicon Pharmaceuticals (NASDAQ: LXRX) 38% HIGHER; Citi upgraded from Neutral to Buy with a price target of $6.00 (from $2.10).
Stitch Fix (NASDAQ: SFIX) 37.9% HIGHER; reported Q1 EPS of $0.09, $0.29 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $490.4 million versus the consensus estimate of $481.17 million. Also announced that... More
After-Hours Stock Movers 12/07: (SFIX) (HOLI) (SMAR) Higher; (MRNS) (IBIO) (ARCT) Lower (more...)
December 7, 2020 5:26 PM ESTAfter-Hours Stock Movers
Stitch Fix (NASDAQ: SFIX) 37.9% HIGHER; reported Q1 EPS of $0.09, $0.29 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $490.4 million versus the consensus estimate of $481.17 million. Also announced that Dan Jedda has joined the company, reporting to Katrina Lake. Jedda will be appointed CFO effective December 9, 2020. Dan Jedda joins the company from Amazon where he was Vice President and CFO for Digital Video (including Amazon Studios), Digital Music, and the Advertising and Corporate Development organizations.
Hollysys Automation (NASDAQ:... More
Sutro Biopharma (STRO) Announces Proposed Public Offering of 5 Million Shares of Common Stock
December 7, 2020 4:01 PM ESTSutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced a proposed underwritten public offering in which it intends to offer and sell 5,000,000... More
Sutro Biopharma Inc. (STRO) Presents Data from Ongoing Phase 1 Dose-Escalation Study for STRO-001 for the Treatment of B-cell Non-Hodgkin Lymphoma at ASH
December 7, 2020 10:04 AM ESTSutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced a poster presentation at the virtual 62nd American Society of Hematology (ASH) Annual Meeting for the ongoing Phase 1 dose-escalation clinical trial for its CD74-targeted antibody drug conjugate (ADC) STRO-001 for patients with late-line Non-Hodgkin Lymphoma (NHL). Additionally, data were presented from preclinical studies conducted in collaboration with researchers from the Fred Hutchinson Cancer Research Center.
"With three product candidates... More
